Narwhal Capital Management’s Pfizer PFE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q1 | – | Sell |
-8,474
| Closed | -$225K | – | 165 |
|
|
2024
Q4 | $225K | Sell |
8,474
-12,071
| -59% | -$327K | 0.02% | 155 |
|
|
2024
Q3 | $595K | Sell |
20,545
-28,883
| -58% | -$843K | 0.05% | 121 |
|
|
2024
Q2 | $1.38M | Sell |
49,428
-31,079
| -39% | -$856K | 0.13% | 90 |
|
|
2024
Q1 | $2.23M | Sell |
80,507
-56,252
| -41% | -$1.56M | 0.22% | 80 |
|
|
2023
Q4 | $3.94M | Sell |
136,759
-26,393
| -16% | -$798K | 0.43% | 64 |
|
|
2023
Q3 | $5.41M | Sell |
163,152
-16,128
| -9% | -$570K | 0.66% | 47 |
|
|
2023
Q2 | $6.58M | Sell |
179,280
-11,969
| -6% | -$466K | 0.77% | 37 |
|
|
2023
Q1 | $7.8M | Sell |
191,249
-28,367
| -13% | -$1.23M | 0.98% | 33 |
|
|
2022
Q4 | $11.3M | Sell |
219,616
-56,636
| -21% | -$2.72M | 1.5% | 20 |
|
|
2022
Q3 | $12.1M | Sell |
276,252
-9,518
| -3% | -$463K | 1.75% | 12 |
|
|
2022
Q2 | $15M | Buy |
285,770
+90,419
| +46% | +$4.61M | 2.05% | 11 |
|
|
2022
Q1 | $10.1M | Buy |
195,351
+4,944
| +3% | +$257K | 1.18% | 27 |
|
|
2021
Q4 | $11.2M | Buy |
190,407
+17,269
| +10% | +$856K | 1.28% | 24 |
|
|
2021
Q3 | $7.45M | Buy |
173,138
+26,510
| +18% | +$1.17M | 0.94% | 34 |
|
|
2021
Q2 | $5.74M | Buy |
146,628
+845
| +0.6% | +$32.9K | 0.72% | 43 |
|
|
2021
Q1 | $5.28M | Sell |
145,783
-6,074
| -4% | -$216K | 0.71% | 42 |
|
|
2020
Q4 | $5.59M | Sell |
151,857
-16,006
| -10% | -$587K | 0.79% | 40 |
|
|
2020
Q3 | $5.84M | Sell |
167,863
-19,498
| -10% | -$684K | 0.94% | 37 |
|
|
2020
Q2 | $5.81M | Sell |
187,361
-19,491
| -9% | -$662K | 1.01% | 33 |
|
|
2020
Q1 | $6.41M | Buy |
206,852
+4,778
| +2% | +$163K | 1.38% | 23 |
|
|
2019
Q4 | $7.51M | Buy |
202,074
+8,841
| +5% | +$315K | 1.38% | 21 |
|
|
2019
Q3 | $6.59M | Sell |
193,233
-1,908
| -1% | -$69.4K | 1.32% | 24 |
|
|
2019
Q2 | $8.02M | Buy |
195,141
+3,123
| +2% | +$124K | 1.66% | 14 |
|
|
2019
Q1 | $7.74M | Sell |
192,018
-1,493
| -0.8% | -$59.8K | 1.68% | 14 |
|
|
2018
Q4 | $8.01M | Sell |
193,511
-2,688
| -1% | -$112K | 1.99% | 9 |
|
|
2018
Q3 | $8.2M | Sell |
196,199
-274
| -0.1% | -$10.5K | 1.81% | 10 |
|
|
2018
Q2 | $6.76M | Sell |
196,473
-1,192
| -0.6% | -$40.7K | 1.57% | 13 |
|
|
2018
Q1 | $6.66M | Buy |
197,665
+17,399
| +10% | +$598K | 1.54% | 15 |
|
|
2017
Q4 | $6.2M | Buy |
180,266
+7,642
| +4% | +$261K | 1.42% | 15 |
|
|
2017
Q3 | $5.85M | Buy |
172,624
+3,926
| +2% | +$126K | 1.45% | 13 |
|
|
2017
Q2 | $5.38M | Buy |
168,698
+21,106
| +14% | +$666K | 1.39% | 16 |
|
|
2017
Q1 | $4.79M | Buy |
147,592
+14,449
| +11% | +$456K | 1.33% | 18 |
|
|
2016
Q4 | $4.1M | Buy |
133,143
+1,054
| +0.8% | +$32.2K | 1.24% | 19 |
|
|
2016
Q3 | $4.25M | Hold |
132,089
| – | – | 1.33% | 19 |
|
|
2016
Q2 | $4.41M | Hold |
132,089
| – | – | 1.39% | 16 |
|
|
2016
Q1 | $3.71M | Buy |
132,089
+1,791
| +1% | +$51.2K | 1.21% | 21 |
|
|
2015
Q4 | $3.99M | Hold |
130,298
| – | – | 1.38% | 17 |
|
|
2015
Q3 | $3.88M | Sell |
130,298
-158
| -0.1% | -$5.07K | 1.45% | 15 |
|
|
2015
Q2 | $4.15M | Buy |
130,456
+171
| +0.1% | +$5.57K | 1.51% | 12 |
|
|
2015
Q1 | $4.3M | Hold |
130,285
| – | – | 1.57% | 9 |
|
|
2014
Q4 | $3.85M | Buy |
130,285
+3,835
| +3% | +$110K | 1.49% | 15 |
|
|
2014
Q3 | $3.55M | Buy |
126,450
+843
| +0.7% | +$23.7K | 1.42% | 14 |
|
|
2014
Q2 | $3.54M | Buy |
125,607
+1,632
| +1% | +$46.5K | 1.35% | 16 |
|
|
2014
Q1 | $3.78M | Buy |
123,975
+1,081
| +0.9% | +$32.2K | 1.57% | 9 |
|
|
2013
Q4 | $3.57M | Buy |
122,894
+2,687
| +2% | +$78.2K | 1.47% | 12 |
|
|
2013
Q3 | $3.28M | Sell |
120,207
-1,212
| -1% | -$33K | 1.57% | 11 |
|
|
2013
Q2 | $3.23M | Buy |
+121,419
| New | +$3.35M | 1.56% | 11 |
|
Other funds holding PFE
TIM
Narwhal Capital Management's PFE Position: Q1 2025 in Review
Narwhal Capital Management sold out of Pfizer (PFE) in Q1 2025, closing a stake of 8,474 shares — an estimated $225K sold.
Narwhal Capital Management first reported a position in PFE in Q2 2013 and held it in 47 quarters. The position peaked at $15M in Q2 2022. 2,930 funds tracked by Wall St. Rank hold PFE as of Q1 2025.
- Narwhal Capital Management reported no remaining Pfizer position as of Q1 2025 after selling out during the quarter.
- Narwhal Capital Management sold 8,474 Pfizer shares in Q1 2025, an estimated $225K.
- Narwhal Capital Management first reported a position in Pfizer in Q2 2013 and held it in 47 quarters.
- Narwhal Capital Management's Pfizer position peaked at $15M in Q2 2022.
- 2,930 funds tracked by Wall St. Rank held Pfizer as of Q1 2025.
Based on Narwhal Capital Management's 13F filing for Q1 2025, filed 23 Apr 2025.